Ribosomal Protein S6 Kinases, 70-kDa
"Ribosomal Protein S6 Kinases, 70-kDa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of ribosomal protein S6 kinases that are considered the major physiological kinases for RIBOSOMAL PROTEIN S6. Unlike RIBOSOMAL PROTEIN S6 KINASES, 90KDa the proteins in this family are sensitive to the inhibitory effects of RAPAMYCIN and contain a single kinase domain. They are referred to as 70kDa proteins, however ALTERNATIVE SPLICING of mRNAs for proteins in this class also results in 85kDa variants being formed.
| Descriptor ID |
D038762
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.862.249 D12.644.360.600.249 D12.776.476.600.249
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ribosomal Protein S6 Kinases, 70-kDa".
Below are MeSH descriptors whose meaning is more specific than "Ribosomal Protein S6 Kinases, 70-kDa".
This graph shows the total number of publications written about "Ribosomal Protein S6 Kinases, 70-kDa" by people in this website by year, and whether "Ribosomal Protein S6 Kinases, 70-kDa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2010 | 0 | 4 | 4 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ribosomal Protein S6 Kinases, 70-kDa" by people in Profiles.
-
Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. J Hematol Oncol. 2021 08 18; 14(1):127.
-
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. Clin Cancer Res. 2020 07 15; 26(14):3720-3731.
-
A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018 05; 8(5):556-567.
-
G protein-dependent signaling triggers a ?-arrestin-scaffolded p70S6K/ rpS6 module that controls 5'TOP mRNA translation. FASEB J. 2018 03; 32(3):1154-1169.
-
Fragment-based design, synthesis, biological evaluation, and SAR of 1H-benzo[d]imidazol-2-yl)-1H-indazol derivatives as potent PDK1 inhibitors. Bioorg Med Chem Lett. 2017 12 15; 27(24):5473-5480.
-
Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention. Cancer Prev Res (Phila). 2017 Nov; 10(11):641-650.
-
Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. J Natl Cancer Inst. 2017 07 01; 109(7).
-
CF3DODA-Me induces apoptosis, degrades Sp1, and blocks the transformation phase of the blebbishield emergency program. Apoptosis. 2017 05; 22(5):719-729.
-
Ginkgo biloba L. attenuates spontaneous recurrent seizures and associated neurological conditions in lithium-pilocarpine rat model of temporal lobe epilepsy through inhibition of mammalian target of rapamycin pathway hyperactivation. J Ethnopharmacol. 2017 May 23; 204:8-17.
-
Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer. Br J Cancer. 2015 Mar 17; 112(6):1042-51.